Breast Cancer and Postmenopausal Obesity: the Risk Factors in this Relationship
Cancer Research Journal
Volume 2, Issue 1, January 2014, Pages: 9-14
Received: Feb. 16, 2014; Published: Mar. 10, 2014
Views 3163      Downloads 211
Authors
Clarissa Germano Barp, Department of Pharmacy, State University of Center-West, Camargo Varela de Sá, 03, Vila Carli, Guarapuava, Paraná, Brazil
Durinézio Jose de Almeida, Department of Biology, State University of Maringá. Colombo Avenue, 5790, Zone 07, Maringá, Paraná, Brazil
Guilherme Barroso Langoni de Freitas, Department of Pharmacy, State University of Center-West, Camargo Varela de Sá, 03, Vila Carli, Guarapuava, Paraná, Brazil; Department of Medicine, Federal University of Paraná (UFPR), Internal Medicine Program, General Carneiro, 181, Alto da Glória, Curitiba, Paraná, Brazil
Article Tools
PDF
Follow on us
Abstract
The prevalence of obesity is increasing rapidly in both the developed and the developing countries, thus contributing to the occurrence of other diseases, e.g. hypertension, diabetes and breast cancer. Breast cancer involves a multifactorial process in which the surrounding microenvironment is known to be of great importance in the development and progression of the disease. Thus, adipose tissue, due to its immunological, metabolic and endocrine properties, may play a crucial role in the onset and progression of the disease. The relationship between obesity and breast cancer needs to be studied and characterized so that more effective treatments can be developed, faster and more secure diagnostic and prognostic tests might emerge and, mainly, so that public policies can be designed to prevent the increasing incidence of the disease related to obesity. The main hypotheses regarding the increased risk of developing breast cancer among obese women, i.e. sex hormones, adipokines, insulin and cytokines, are discussed in this review.
Keywords
Obesity, Breast cancer, Adipokines, Sex hormones, Cytokines, Insulin
To cite this article
Clarissa Germano Barp, Durinézio Jose de Almeida, Guilherme Barroso Langoni de Freitas, Breast Cancer and Postmenopausal Obesity: the Risk Factors in this Relationship, Cancer Research Journal. Vol. 2, No. 1, 2014, pp. 9-14. doi: 10.11648/j.crj.20140201.12
References
[1]
Robbins & Cotran - Patologia - Bases Patológicas das Doenças - 8ª Ed. 2010. Pg 446-447.
[2]
Undurti N D; M.D.; F.A.M.S. (2010) Obesity: Genes, brain, gut, and environment. Nutrition 26, 459–473.
[3]
Doyle S L, Donohoe C L, Lysaght J, Reynolds J V (2012) Symposium 3: Obesity-related cancers - Visceral obesity, metabolic syndrome, insulin resistance and câncer. P Nutr Soc. 71, 181–189.
[4]
http://www.cancerresearchuk.org/cancer-info/cancerstats/reports/
[5]
C. Pichard C, Plu-Bureau G, Neves e Castro M, Gompel A. Insulin resistance, obesity and breast cancer risk. Maturitas. Volume 60, Issue 1, 20 May 2008, Pages 19–30.
[6]
Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat (2010) 119:367–377.
[7]
Lautenbach A, Budde A, Wrann C D, Teichmann B, Vieten G, Karl T, Nave H (2009) Obesity and the Associated Mediators Leptin, Estrogen and IGF-I Enhance the Cell Proliferation and Early Tumorigenesis of Breast Cancer Cells. Nutr Cancer 61(4), 484–491.
[8]
Bergstrom A, Pisani P, Tenet V, Wolk A, Adami H (2001) Overweight as an avoidable cause of cancer in europe. Int J Cancer: 91, 421–430.
[9]
Jardé T, Perrier S, Vasson M, Caldefie-Chézet F (2011) Molecular mechanisms of leptin and adiponectin in breast câncer. Eur J Cancer 47, 33–4 3.
[10]
Place A E, Huh S J, Polyak K (2011) The microenvironment in breast câncer progression: biology and implications for treatment. Breast Cancer Res, 13:227.
[11]
Clamp A, Danson S, Clemons M (2003) Hormonal and genetic factors for breast cancer risk. J Roy Coll Surg Edin 23-31.
[12]
Bellemare V, Laberge P, Noël S, Tchernof A, Luu-The V (2009) Differential estrogenic 17_-hydroxysteroid dehydrogenase activity and type 12 17_-hydroxysteroid dehydrogenase expression levels in preadipocytes and differentiated adipocytes. J Steroid Biochem 114, 129–134.
[13]
Kumar S, Lata K, Mukhopadhyay S, Mukherjee T K (2010) Role of estrogen receptors in pro-oxidative and anti-oxidative actions of estrogens: A perspective. Biochim Biophys Acta 1800, 1127–1135.
[14]
Carruba G (2007) Estrogen and Prostate Cancer: An Eclipsed Truth in na Androgen-Dominated Scenario. J Cell Biochem 102, 899–911.
[15]
Helguero L A, Faulds M H, Gustafsson J K, Haldosén L (2005) Estrogen receptors alfa (ERa) and beta (ERb) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24, 6605–6616.
[16]
Leung Y, Lee M, Lam H, Tarapore P, Ho S (2012) Estrogen receptor-beta and breast cancer: Translating biology into clinical practice. Steroids 77, 727–737.
[17]
Rose D.P, Vona-Davis L (2010) Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 66, 33–38.
[18]
Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Penault-Llorca F, Guillot J, Vasson M P (2008) Leptin and leptin receptor involvement in cancer development: A study on human primary breast carcinoma. Oncol Rep 19, 905-911.
[19]
Giordano C, Vizza D, Panza S, Barone I, Bonofiglio D, Lanzino M, Sisci D, Amicis F De, Fuqua S A W, Catalano S, Ando S (2012) Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol 1-13.
[20]
Marotta L L C, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker S R, Bloushtain-Qimron N, Kim J J, Choudhury S A, Maruyama R, Wu Z, Gönen M, Mulvey L A, Bessarabova M O, Huh S J, Silve S J, Kim S Y, Park S Y, Lee H E, Anderson K S, Richardson A L, Nikolskaya T, Nikolsky Y, Liu X S, Root D E, Hahn W C, Frank D A, Polyak K (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell– like breast cancer cells in human tumors. J Clin Invest http://www.jci.org Volume 121 Number 7.
[21]
Garofalo C, Koda M, Cascio S (2006) Increased Expression of Leptin and the Leptin Receptor as a Marker of Breast Cancer Progression: Possible Role of Obesity-Related Stimuli. Clin Cancer Res 12, 1447-1453.
[22]
Ramos-Nino ME. The Role of Chronic Inflammation in Obesity-Associated Cancers. ISRN Oncology. Volume 2013 (2013), Article ID 697521, 25 pages.
[23]
Housa D, Housová J, Vernerová Z, Haluzík M (2006) Adipocytokines and Câncer. Physiol Res 55, 233-244.
[24]
Gilbert C A, Slingerland J M (2013) Cytokines, Obesity, and Cancer: New Insights on Mechanisms Linking Obesity to Cancer Risk and Progression. Annu Rev Med 64, 45–57.
[25]
Nicolini A, Carpi A, Rossi G (2006) Cytokines in breast câncer. Cytokine Growth F R 17, 325–337.
[26]
Dethlefsen C, Højfeldt G, Hojman P (2013) The role of intratumoral and systemic IL-6 in breast câncer. Breast Cancer Res Tr 138, 657–664.
[27]
Bogin L, Papa M Z, Polak-Charcon S, Degani H (1998) TNF-induced modulations of phospholipid metabolism in human breast cancer cells. Biochim Biophys Acta 1392, 217-232.
[28]
Horssen R V, Hagen T L M T (2006) Eggermont, A. M. M. TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. The Oncologist 11, 397–408.
[29]
Rivas M A, Carnevale R P, Proiettia C J, Rosemblit C, Beguelin W, Salatino M, Charreau E H, Frahm I, Sapia S, Brouckaert P, Elizalde P V, Schillaci R (2008) TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways. Exp Cell Res 314, 509–529.
[30]
Yuan L, Jiang R, Yang Y, Ding S, Deng H (2012) 1,25-Dihydroxyvitamin D3 inhibits growth of the breast cancercell line MCF-7 and downregulates cytochrome P4501B1through the COX-2/PGE2 pathway. Oncol Rep 28, 2131-2137.
[31]
Holt D, Ma X, Kundu N, Collin P D, Fulton A M (2012) Modulation of host natural killer cell functions in breast câncer via prostaglandin E2 receptors EP2 and EP4. J Immunother 35(2), 179–188.
[32]
Reader J, Holt D, Fulton A (2011) Prostaglandin E2 EP Receptors as Therapeutic Targets in Breast Câncer. Cancer Metast Rev 30(0), 449–463.
[33]
Thill M, Hoellen F, Becker S, Dittmer C, Fischer D, Kummel S, Salehin D, Friedrich M, Koster F, Diedrich K, Cordes T (2012) Expression of Prostaglandin- and Vitamin D-metabolising Enzymes in Benign and Malignant Breast Cells. Anticancer Res 32, 367-372.
[34]
Campagnoli C, Pasanisi C, Castellano I, Abba` C, Brucato T, Berrino F (2013) Postmenopausal breast cancer, androgens, and aromatase inhibitors. Breast Cancer Res Tr 139, 1–11.
[35]
Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res 2009, 11:212.
[36]
Aspinall S R, Cook D B, Shenton B K, Griffiths A.B, Griffith C D M, Bliss R D, Lennard T W J (2003) Serum adrenal androgens in women with primary operable breast cancer and their relationship with age and body mass index. Breast 12, 63–71.
[37]
Somboonporn W, Davis S R (2004) Postmenopausal testosterone therapy and breast cancer risk. Maturitas 49, 267–275.
[38]
Suzuki T, Miki Y, Takagi K, Hirakawa H, Moriya T, Ohuchi N, Sasano H (2010) Androgens in human breast carcinoma. Med Mol Morphol 43, 75–81.
[39]
Tiefenbacher K, Daxenbichler G. The Role of Androgens in Normal and Malignant Breast Tissue. Breast Care (Basel). 2008;3(5):325-331. Epub 2008 Oct 16.
[40]
Perks C M, Holly J M P (2011) Mechanisms Underlying the Relationship Between Obesity and Breast Câncer. Endocrin Metab Clin 40, 485–507.
[41]
Patterson R E, Rock C L, Kerr J, Natarajan L, Marshall S J, Pakiz B, Cadmus-Bertram L A (2013) Metabolism and Breast Cancer Risk: Frontiers in Research and Practice. J Acad Nutr Diet 113, 288-296.
[42]
Vecchia C, Giordano S H, Hortobagyi G N, Chabner B (2011) Overweight, Obesity, Diabetes, and Risk of Breast Cancer: Interlocking Pieces of the Puzzle. The Oncologist 16, 726–729.
[43]
Goodwin P J, Stambolicb V (2011) Obesity and insulin resistance in breast cancer – Chemoprevention strategies with a focus on metformin. The Breast 20, S3, S31–S35.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186